Tesamorelin

What Tesamorelin Does

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that extends its biological activity. It is the only GHRH analog with full FDA approval — marketed as Egrifta SV for reducing visceral abdominal fat in HIV-positive patients with lipodystrophy.

The mechanisms that matter for your protocol:

• GHRH receptor agonism — binds the GHRH receptor on the anterior pituitary with higher affinity and longer activity than native GHRH or sermorelin
• Selective visceral fat reduction — clinical trials demonstrated preferential loss of visceral adipose tissue (VAT) over subcutaneous fat. The mechanism is GH-mediated lipolysis, which is more active in visceral fat due to higher beta-adrenergic receptor density
• IGF-1 elevation — increases IGF-1 by 30–80%, greater than sermorelin but comparable to CJC-1295
• Pulsatile GH release — like other GHRH analogs, preserves the body’s natural GH rhythm and somatostatin feedback
• Hepatic fat reduction — reduces liver fat (NAFLD) through GH-driven hepatic fat oxidation. Phase 2 NASH trial data showed significant liver fat reduction

Tesamorelin is unique among GH peptides because it has the strongest clinical evidence for fat-specific effects — not just “GH goes up” but measurable, CT-verified visceral fat reduction.

The Clinical Evidence

LIPO-010 and LIPO-011 Trials

These Phase 3 trials established tesamorelin’s FDA approval:

Metric	Tesamorelin 2 mg	Placebo
Visceral fat change (26 weeks)	-18%	-2%
Trunk fat change	-10%	-1%
IGF-1 increase	+81%	+3%
Waist circumference	Significant reduction	No change
Limb fat	No significant change	No change

The visceral-selective fat loss is the critical finding. Tesamorelin didn’t just reduce overall body fat — it specifically targeted the visceral depot that drives metabolic disease, cardiovascular risk, and insulin resistance.

NAFLD/NASH Data

A Harvard-led randomized trial (Stanley TL et al., Lancet HIV, 2023) demonstrated:

• 37% reduction in hepatic fat fraction at 12 months
• Significant improvement in liver fibrosis markers
• Effect maintained throughout treatment period

This positions tesamorelin as potentially valuable for the metabolic syndrome population beyond HIV.

Dosing Protocol

FDA-Approved Protocol

Parameter	Detail
Dose	2 mg/day
Timing	Once daily
Injection site	Subcutaneous (abdomen)
Duration	26 weeks minimum, reassess at 26 weeks
Monitoring	IGF-1 at baseline and periodic intervals

The FDA label specifies: if trunk fat has not decreased after 26 weeks, discontinue. Responders should continue for sustained benefit.

Anti-Aging / Off-Label Protocol

Parameter	Detail
Dose	1–2 mg/day
Timing	Before bed, fasted (same rules as sermorelin)
Duration	6–12 months continuous
Monitoring	IGF-1, fasting glucose, HbA1c at 3 and 6 months

Some clinics start at 1 mg/day and titrate to 2 mg based on IGF-1 response and tolerance. The lower dose reduces cost while still providing meaningful GH elevation.

Timing Rules

Same as all GHRH analogs:

1. Fasted state — no food for 90+ minutes before injection. Insulin blunts GH release.
2. Pre-sleep preferred — amplifies the natural nocturnal GH pulse.
3. Consistent timing — inject at the same time daily for stable GH patterning.

Tesamorelin vs Other GHRH Analogs

Feature	Tesamorelin	Sermorelin	CJC-1295 (no DAC)
FDA status	Approved (Egrifta SV)	Orphan drug designation (discontinued)	Not approved
Half-life	~26 minutes	~10 minutes	~30 minutes
GH potency	High	Low-moderate	Moderate-high
IGF-1 increase	30–80%	15–30%	30–50%
Visceral fat data	Phase 3 CT-verified	Limited	Limited
Liver fat data	Yes (Phase 2 NASH)	No	No
Desensitization	Moderate	Moderate	Minimal
Cost (pharma)	$500–1,000/mo	$150–300/mo (clinic)	N/A
Cost (research)	$150–300/mo	$50–100/mo	$50–100/mo
Availability	Prescription required	Clinic or research	Research only

When to choose tesamorelin: You want the strongest evidence-based GHRH analog, specifically for visceral fat reduction, and can afford pharmaceutical or research-grade pricing.

When to choose CJC-1295 + Ipamorelin: You want cost-effective GH optimization, are comfortable with research-grade peptides, and your primary goals are anti-aging and body recomposition rather than visceral-specific fat targeting.

What to Expect

Timeline

Timeframe	Expected Changes
Week 1–2	Improved sleep quality, potential injection-site reactions
Week 4–8	Measurable IGF-1 elevation on blood work
Week 12–16	Visible reduction in abdominal circumference
Week 26	CT-verified visceral fat reduction (clinical endpoint)
Month 6–12	Continued progressive visceral fat loss, improved metabolic markers

Realistic Expectations

• Average visceral fat reduction: 15–20% at 6 months
• This is visceral fat, not total weight. The scale may not move dramatically, but waist circumference and CT imaging will show the difference.
• Subcutaneous fat loss is modest. Tesamorelin preferentially targets visceral depots. For subcutaneous fat loss, GLP-1 agonists are more effective.
• Effects are reversible. Visceral fat returns over 3–6 months after discontinuation. This is a chronic treatment, not a cure.

Safety & Contraindications

Side Effects

Side Effect	Frequency	Notes
Injection-site reactions	Very common (24%)	Erythema, pruritus, pain — rotate sites
Arthralgia (joint pain)	Common (13%)	GH-mediated, usually mild
Peripheral edema	Common (6%)	Water retention, dose-dependent
Hyperglycemia	Common	Monitor glucose, especially in prediabetics
Headache	Occasional	Usually first 2 weeks
Paresthesia (tingling)	Occasional	GH effect on nerve tissue, usually transient

Contraindications

• Active malignancy — GH stimulates cell proliferation. Absolute contraindication.
• Pituitary pathology — disruption of the hypothalamic-pituitary axis (surgery, radiation, tumor)
• Hypersensitivity to tesamorelin or mannitol
• Pregnancy — FDA Category X (shown to cause fetal harm in animal studies)
• Diabetic retinopathy — GH worsens neovascularization

Drug Interactions

• Diabetes medications — tesamorelin may require insulin or oral hypoglycemic dose adjustments
• Cortisone/prednisone — glucocorticoids blunt GH response and counteract visceral fat reduction
• Other GH secretagogues — do not stack tesamorelin with CJC-1295 or sermorelin (same receptor pathway, no additive benefit, increased side effects)

Blood Work

Marker	When	Why
IGF-1	Baseline, 3mo, 6mo	Confirm GH axis activation, monitor for excess
Fasting glucose	Baseline, 3mo, 6mo	GH impairs glucose tolerance
HbA1c	Baseline, 6mo	Long-term glucose monitoring
Lipid panel	Baseline, 6mo	GH affects lipid metabolism
Liver enzymes (ALT/AST)	Baseline, 6mo	Especially if NAFLD is present

Research & Citations

Phase 3 approval data: Falutz J et al., “Effects of tesamorelin on body composition in HIV-infected patients with abdominal fat accumulation,” Journal of Clinical Endocrinology & Metabolism (2007). Demonstrated 18% visceral fat reduction vs placebo over 26 weeks with CT verification.

NAFLD data: Stanley TL et al., “Tesamorelin reduces hepatic fat and hepatic fibrosis in people with nonalcoholic fatty liver disease and HIV,” Lancet HIV (2023). Randomized controlled trial showing 37% hepatic fat reduction at 12 months.

Long-term safety: Theratechnologies published 52-week extension data showing sustained visceral fat reduction and acceptable safety profile with continued tesamorelin use.

Related Protocols

• Sermorelin Protocol — the original GHRH analog, more affordable
• CJC-1295 Protocol — research-grade GHRH alternative
• Ipamorelin Protocol — GHRP pairing partner
• AOD-9604 Protocol — HGH fragment for targeted fat loss
• GH Peptides Compared — full comparison of all GH options
• Reconstitution Calculator — exact dosing math for your vials